Novavax | NVAX - Des Atouts





Des Atouts Changement Date
Adma Biologics USD 624.24M 55.56M 2025-12
Agenus USD 226.8M 7.09M 2025-12
AstraZeneca USD 114.02B 59M 2026-03
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
Cassava Sciences USD 118.35M 11.38M 2025-12
Geron USD 570.54M 3.16M 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
MannKind USD 792.18M 297.54M 2025-12
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Moderna USD 11.49B 850M 2026-03
Novartis USD 110.95B 3.66B 2025-12
Novavax USD 1.18B 3.38M 2025-12
Pfizer USD 207.62B 542M 2026-03
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
TG Therapeutics USD 1.06B 38.23M 2025-12